Literature DB >> 20842739

Aspirin use is associated with an improved long-term survival in an unselected population presenting with unstable angina.

Louai Razzouk1, Verghese Mathew, Ryan J Lennon, Ashish Aneja, Joshua I Mozes, Heather J Wiste, Paul Muntner, James H Chesebro, Michael E Farkouh.   

Abstract

BACKGROUND: Few published data are available on the benefits of aspirin use in patients with unstable angina (UA). HYPOTHESIS: Aspirin use carries a mortality benefit in a population-based cohort of patients presenting with UA.
METHODS: All residents of Olmsted County, Minnesota presenting to local emergency departments with acute chest pain from January 1985 through December 1992 having symptoms consistent with UA were identified through medical records. A total of 1628 patients were identified with UA and were stratified by aspirin use in-hospital and at discharge. Cardiovascular mortality and nonfatal myocardial infarction and stroke were assessed over a median of 7.5 years follow-up and all-cause mortality data over a median of 16.7 years. The mean age of patients with UA was 65 years, and 60% were men.
RESULTS: After a median of 7.5 years follow-up, all-cause and cardiovascular-mortality rates were lower among patients prescribed versus not prescribed aspirin on discharge. There were 949 postdischarge deaths over the median follow-up of 16.7 years. After multivariable adjustment, aspirin use at discharge was associated with a lower long-term mortality (hazard ratio 0.78; 95% confidence interval, 0.65-0.93).
CONCLUSIONS: Aspirin use at hospital discharge following UA is associated with a reduction in long-term mortality. This long-term study extends prior trial results from select populations to a population-based cohort.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842739      PMCID: PMC3785089          DOI: 10.1002/clc.20769

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  19 in total

1.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.

Authors:  E M Antman; M Cohen; P J Bernink; C H McCabe; T Horacek; G Papuchis; B Mautner; R Corbalan; D Radley; E Braunwald
Journal:  JAMA       Date:  2000-08-16       Impact factor: 56.272

2.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

3.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

4.  Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.

Authors:  Ewurabena Simpson; Christine Beck; Hugues Richard; Mark J Eisenberg; Louise Pilote
Journal:  Am Heart J       Date:  2003-03       Impact factor: 4.749

Review 5.  The mechanism of action of aspirin.

Authors:  J R Vane; R M Botting
Journal:  Thromb Res       Date:  2003-06-15       Impact factor: 3.944

6.  A case-control study of regular aspirin use and coronary deaths.

Authors:  C H Hennekens; L K Karlson; B Rosner
Journal:  Circulation       Date:  1978-07       Impact factor: 29.690

7.  The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.

Authors: 
Journal:  Circulation       Date:  1980-12       Impact factor: 29.690

8.  Inhibition of platelet prostaglandin synthetase by oral aspirin.

Authors:  J W Burch; N Stanford; P W Majerus
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

9.  Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study.

Authors:  Birgit Frilling; Rudolf Schiele; Anselm Kai Gitt; Ralf Zahn; Steffen Schneider; Hans-Georg Glunz; Ulf Gieseler; Edwin Jagodzinski; Jochen Senges
Journal:  Am Heart J       Date:  2004-08       Impact factor: 4.749

10.  Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.

Authors: 
Journal:  Circulation       Date:  1980-09       Impact factor: 29.690

View more
  2 in total

1.  Dan-Shen-Yin protects the heart against inflammation and oxidative stress induced by acute ischemic myocardial injury in rats.

Authors:  Kui-Po Yan; Yong Guo; Zhihua Xing; Xi Huang; Shengping Dai; Min Duan; Xinhua Sun; Wei Huang; Weijun Peng
Journal:  Exp Ther Med       Date:  2011-12-05       Impact factor: 2.447

2.  Prognostic utility of cardiovascular magnetic resonance upright maximal treadmill exercise testing.

Authors:  Bunyapon Sukpraphrute; Brandon C Drafts; Pairoj Rerkpattanapipat; Timothy M Morgan; Paul M Kirkman; William O Ntim; Craig A Hamilton; Robert L Cockrum; W Gregory Hundley
Journal:  J Cardiovasc Magn Reson       Date:  2015-11-25       Impact factor: 5.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.